Picard Medical Posts 12.5% Revenue Rise to $4.9M and $11.5M Year-End Cash
Picard Medical’s revenue rose 12.5 percent to $4.94 million in 2025, with product sales comprising $4.75 million and gross margin narrowing to a 4.1 percent loss. Year-end cash reached $11.5 million after $27.1 million of financing, but net loss widened to $27.0 million.
1. Full Year 2025 Financial Results
In 2025 Picard Medical reported total revenue of $4.94 million, a 12.5 percent increase from $4.39 million a year earlier, driven by $4.75 million in product revenue and $0.19 million in rental sales. Gross margin contracted to a 4.1 percent loss and operating loss narrowed slightly to $13.3 million, but net loss expanded to $27.0 million.
2. Balance Sheet Strengthening
Cash and equivalents totaled $11.5 million at year-end 2025, up from $0.1 million, following $17.4 million in net equity financing proceeds and $9.7 million in debt financing. The company also converted convertible debt and eliminated related derivative liabilities, enhancing its financial flexibility.
3. SynCardia Adoption Trends
SynCardia Total Artificial Heart product sales accounted for 96 percent of 2025 revenue, reflecting continued adoption across leading transplant centers. More than 2,100 implants have been performed globally to date, underscoring the device’s status as the most widely used total artificial heart system.
4. Outlook and Capital Needs
Management plans to invest further in commercialization, manufacturing scale and product development, while acknowledging additional capital requirements to support operations and strategic growth initiatives. An investor call scheduled for March 25 will provide more operational updates.